Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Immatics N.V.
  6. Summary
    IMTX   NL0015285941

IMMATICS N.V.

(IMTX)
  Report
Delayed Quote. Delayed Nasdaq - 06/11 04:00:00 pm
12.26 USD   -1.37%
05/26IMMATICS Ná : PRESS RELEASE (Form 6-K)
PU
05/26PRESS RELEASE : Immatics Announces Changes to its Board of Directors
DJ
05/18IMMATICS Ná : PRELIMINARY NOTE (Form 6-K)
PU
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/07/2021 06/08/2021 06/09/2021 06/10/2021 06/11/2021 Date
12.14(c) 12.17(c) 12.34(c) 12.43(c) 12.26(c) Last
218 638 74 308 82 603 44 671 39 250 Volume
+1.08% +0.25% +1.40% +0.73% -1.37% Change
More quotes
Financials (USD)
Sales 2021 41,8 M - -
Net income 2021 -108 M - -
Net cash position 2021 158 M - -
P/E ratio 2021 -7,19x
Yield 2021 -
Sales 2022 42,8 M - -
Net income 2022 -137 M - -
Net Debt 2022 - - -
P/E ratio 2022 -6,03x
Yield 2022 -
Capitalization 771 M 771 M -
EV / Sales 2021 14,7x
Capi. / Sales 2022 18,0x
Nbr of Employees 285
Free-Float 55,4%
More Financials
Company
Immatics NV is a clinical-stage biopharmaceutical company that is based in the Netherlands. The Company is focused on the discovery and development of T-Cell eceptors with the goal of enabling a robust and specific T-Cell response against these targets. The Company develops targeted immunotherapies with an emphasis on treating solid tumors through two distinct therapeutic modalities: Adoptive Cell Therapies (ACT)... 
More about the company
Ratings of Immatics N.V.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about IMMATICS N.V.
05/26IMMATICS Ná : PRESS RELEASE (Form 6-K)
PU
05/26PRESS RELEASE : Immatics Announces Changes to its Board of Directors
DJ
05/18IMMATICS Ná : PRELIMINARY NOTE (Form 6-K)
PU
05/18SECTOR UPDATE : Health Care Stocks Mixed Premarket Tuesday
MT
05/18IMMATICS Ná : Posts Wider Q1 Loss
MT
05/18PRESS RELEASEá : Immatics Announces First Quarter -3-
DJ
05/18PRESS RELEASE : Immatics Announces First Quarter 2021 Financial Results and Busi..
DJ
05/18PRESS RELEASEá : Immatics Announces First Quarter -2-
DJ
05/12IMMATICS Ná : has selected a clinical lead candidate for the IMA402 program and ..
PU
05/11IMMATICS Ná : TCER IMA402 Preclinical Data Presentation at PEGS Boston 2021
PU
05/11IMMATICS Ná : 20210503 PEGS Immatics final.pdf
PU
05/11PRESS RELEASE : Immatics Presents Preclinical Proof-of-Concept Data for TCR Bisp..
DJ
05/11PRESS RELEASE : AMSilk raises EUR 29M to accelerate commercialization of its hig..
DJ
05/11PRESS RELEASE : MIG portfolio company AMSilk completes EUR29 million financing r..
DJ
04/27PRESS RELEASE : MIG AG records 2020 as the most successful year in its company h..
DJ
More news
News in other languages on IMMATICS N.V.
05/26GlobeNewswire/Immatics gibt personelle Veränderungen in Aufsichtsrat bekannt
05/26Immatics gibt personelle Veränderungen in Aufsichtsrat bekannt
05/18GlobeNewswire/Immatics veröffentlicht Ergebnisse -2-
05/18GlobeNewswire/Immatics veröffentlicht Ergebnisse -3-
05/18GlobeNewswire/Immatics veröffentlicht Ergebnisse des ersten Quartals 2021 sow..
More news
Analyst Recommendations on IMMATICS N.V.
More recommendations
Chart IMMATICS N.V.
Duration : Period :
Immatics N.V. Technical Analysis Chart | IMTX | NL0015285941 | MarketScreener
Technical analysis trends IMMATICS N.V.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 23,75 $
Last Close Price 12,26 $
Spread / Highest target 145%
Spread / Average Target 93,7%
Spread / Lowest Target 55,0%
EPS Revisions
Managers and Directors
NameTitle
Harpreet Singh-Jasuja Chief Executive Officer & Managing Director
Arnd Christ Chief Financial Officer
Peter Alan ChambrÚ Chairman-Supervisory Board
Cedrik M. Britten Chief Medical Officer
Steffen Walter Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
IMMATICS N.V.13.62%771
MODERNA, INC.109.49%87 874
LONZA GROUP AG16.32%54 656
IQVIA HOLDINGS INC.35.87%46 658
CELLTRION, INC.-26.04%32 458
SEAGEN INC.-10.60%28 416